RxDoctor Payments Data

Jonathan Perkins

Pediatric Otolaryngology · Seattle, WANPI 1104907468

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Novartis accounts for 70.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $3,330 and has fallen 67.2% since, to $1,093 in 2025.

$6,493in general payments, 2019–2025

Across 13 payments — averaging $499.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5K
  • Merck$2K
$1,565,682in research payments, 2019–2025

Across 13 payments — averaging $120,437 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.1M
  • Merck$425K

What the payments were for

  • Consulting fees$3,33051%
  • Travel & lodging$2,06832%
  • Food & beverage$1,09617%

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis10$4,558
Merck3$1,936

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric otolaryngology providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Other pediatric otolaryngology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →